The Therapeutic Effects of Fenofibrate on Blood Serum Lipid in Type II Diabetic Patients in El-beida, Libya
DOI:
https://doi.org/10.54172/mjsc.v34i3.280Keywords:
Diabetes mellitus, lipids, fenofibrateAbstract
The risks of dyslipidemia and cardiovascular diseases are well known to be increased in diabetic patients. Moreover, the therapeutic response of fenofibrate drug on blood serum lipid is also known. However, previous studies did not compare the outcomes of fenofibrate on blood serum levels in patients with type II diabetes mellitus with non-diabetic patients. The purpose of this study was to analyze the outcomes of fenofibrate on blood serum lipid profiles in hyperlipidemic patients with type II diabetes mellitus compared to hyperlipidemic patients without diabetes mellitus. This study was conducted on 40 type II diabetic patients and 30 non-diabetic patients. Their ages varied 30-55 years and all of them were hyperlipidemic. Blood serum lipid levels were measured before and once treatment at 1, 2, and 4 months. It was found that the levels of S. Total sterol and S. LDL-C were less in diabetic patients than in non-diabetic patients once they were exploited the different doses of fenofibrate, whereas the changes in S. HDL-C and S. triglyceride were nearly similar in each. Furthermore, it was noticed that just about the same responses of S. Total sterol and S. LDL-C reduction were achieved in diabetic patients once they were using a higher dose than that used for non-diabetic patients. Thus, higher doses of fenofibrate are required to reduce blood serum lipid levels in diabetic patients as compared to non-diabetic patients.
Downloads
References
Austin, M., Breslow, J., Hennekens, C., Buring, J., & Willett, W. (1988). Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. Jama, 260, 1917-1921. DOI: https://doi.org/10.1001/jama.260.13.1917
Daniel, M. J. (2011). Lipid management in patients with type 2 diabetes. American health & drug benefits, 4(5), 312.
Elisaf, M. (2002). Effects of fibrates on serum metabolic parameters. Current medical research and opinion, 18(5), 269-276. DOI: https://doi.org/10.1185/030079902125000516
Elkeles, R. S., Diamond, J. R., Poulter, C., Dhanjil, S., Nicolaides, A. N., Mahmood, S., . . . Feher, M. D. (1998). Cardiovascular outcomes in type 2 diabetes: A double-blind placebo-controlled study of bezafibrate: The St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes care, 21(4), 641-648. DOI: https://doi.org/10.2337/diacare.21.4.641
Goldberg, R. B., Mellies, M. J., Sacks, F. M., Moyé, L. A., Howard, B. V., Howard, W. J., . . . Braunwald, E. (1998). Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation, 98(23), 2513-2519. DOI: https://doi.org/10.1161/01.CIR.98.23.2513
Hirano, T., Ito, Y., Koba, S., Toyoda, M., Ikejiri, A., Saegusa, H., . . . Yoshino, G. (2004). Clinical significance of small dense low-density lipoprotein cholesterol levels determined by the simple precipitation method. Arteriosclerosis, thrombosis, and vascular biology, 24(3), 558-563. DOI: https://doi.org/10.1161/01.ATV.0000117179.92263.08
Ikejiri, A., Hirano, T., Murayama, S., Yoshino, G., Gushiken, N., Hyodo, T., . . . Adachi, M. (2004). Effects of atorvastatin on triglyceride-rich lipoproteins, low-density lipoprotein subclass, and C-reactive protein in hemodialysis patients. Metabolism, 53(9), 1113-1117. DOI: https://doi.org/10.1016/j.metabol.2004.01.011
Investigators, D. A. I. S. (2001). Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. The Lancet, 357(9260), 905-910. DOI: https://doi.org/10.1016/S0140-6736(00)04209-4
Keating, G. M., & Ormrod, D. (2002). Micronised fenofibrate. Drugs, 62(13), 1909-1944. DOI: https://doi.org/10.2165/00003495-200262130-00013
Kothari, V., Stevens, R. J., Adler, A. I., Stratton, I. M., Manley, S. E., Neil, H. A., & Holman, R. R. (2002). UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke, 33(7), 1776-1781. DOI: https://doi.org/10.1161/01.STR.0000020091.07144.C7
Massing, M. W., Foley, K. A., Sueta, C. A., Chowdhury, M., Biggs, D. P., Alexander, C. M., & Simpson, R. J. (2003). Trends in lipid management among patients with coronary artery disease: has diabetes received the attention it deserves? Diabetes care, 26(4), 991-997. DOI: https://doi.org/10.2337/diacare.26.4.991
Parhofer, K. G., Laubach, E., & Barrett, P. H. R. (2003). Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. Journal of lipid research, 44(6), 1192-1198. DOI: https://doi.org/10.1194/jlr.M300011-JLR200
Rubins, H. B., Robins, S. J., Collins, D., Nelson, D. B., Elam, M. B., Schaefer, E. J., . . . Anderson, J. W. (2002). Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Archives of internal medicine, 162(22), 2597-2604. DOI: https://doi.org/10.1001/archinte.162.22.2597
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., . . . McInnes, G. T. (2001). Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. The Lancet, 361(9364), 1149-1158. DOI: https://doi.org/10.1016/S0140-6736(03)12948-0
Westphal, S., Dierkes, J., & Luley, C. (2001). Effects of fenofibrate and gemfibrozil on plasma homocysteine. The Lancet, 358(9275), 39-40. DOI: https://doi.org/10.1016/S0140-6736(00)05271-5
Yoshino, G., Hirano, T., & Kazumi, T. (2002). Treatment of small dense LDL. Journal of atherosclerosis and thrombosis, 9(6), 266-275 DOI: https://doi.org/10.5551/jat.9.266
Downloads
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright of the articles Published by Almukhtar Journal of Science (MJSc) is retained by the author(s), who grant MJSc a license to publish the article. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors and cite MJSc as original publisher. Also they accept the article remains published by MJSc website (except in occasion of a retraction of the article).
